

Figure 1. IL-33 Selectively Induces IL-5 Production by Memory Th2 Cells

(A) Quantitative RT-PCR analysis of *I11r1* in the indicated cell types. Relative expression (normalized to *Hprt*) is shown with SDs.

(B) Expression profiles of ST2 on the indicated cell types.

(C) Expression profiles of ST2 on memory Th2 cells before (blue) and after (red) culture with IL-33.

(D) Memory and effector Th2 cells were cultured with IL-33 for 5 days. The cultured cells were stimulated with immobilized anti-TCR β for 6 hr. Intracellular-staining profiles of IL-5 and IL-4 are shown.

(E) Intracellular-staining profiles of IL-13 in effector and memory Th2 cells before and after culture with IL-33 are shown.

(F) Quantitative RT-PCR analysis of the indicated genes in memory Th2 cells before and after culture with IL-33.

More than five independent experiments were performed and showed similar results (** $p < 0.01$; NS, not significant; Mann-Whitney U test; A–F). Three technical replicates were performed with quantitative RT-PCR (A and F). See also Figure S1.

transcription (H3-K4 trimethylation and H3-K9 acetylation) and higher modifications associated with genetic repression (H3-K27 trimethylation) than did effector Th2 cells (Figure 2B), indicating that these modifications were not efficiently maintained during the transition to the memory phase. However, after stimulation of memory Th2 cells with IL-33 (without TCR stimulation), H3-K4 trimethylation and H3-K9 acetylation increased and H3-K27 trimethylation decreased at the *I15* locus, indicating that IL-33 could restore the chromatin-modification signature observed in IL-5-producing effector Th2 cells. In contrast to histone modifications at the *I15* locus, those at the other Th2 cell cytokine-encoding loci (*I14p*, *I13p*, and Va enhancer) were not obviously affected by IL-33 stimulation (Figures S2A and S2B). We also observed increased H3-K4 trimethylation and H3-K9 acetylation at the *I11r1* locus in IL-33-stimulated memory Th2 cells (Figures S2C and S2D). These changes in histone modifications at the *I15* locus were specific to IL-33 because no obvious change was detected in memory Th2 cells treated with IL-2, IL-7, or IL-25 (Figure S2E). It has previously been shown that

like IL-33, a combination of IL-2 and IL-25 can induce IL-5 production in ILC2s (Furusawa et al., 2013). We examined the synergistic effect of IL-2 and IL-25 on IL-5 production by memory Th2 cells, and indeed cultivation with IL-2 and IL-25, similar to IL-33 cultivation, increased IL-5 production in memory Th2 cells (Figure S2F). Next, we performed ChIP assays to assess whether the chromatin remodeling at the *I15* locus of memory Th2 cells was induced by the combination of IL-2 and IL-25. Active histone modifications were increased and repressive histone modifications were decreased at the *I15* locus in memory Th2 cells after culture with both IL-2 and IL-25 (Figure S2G). The IL-33-induced histone modifications at the *I15* locus were accompanied by enhanced recruitment of p300, a component of the histone acetyl transferase (HAT) complex, and RNA polymerase II (pol II) (Figure 2C). Stronger binding of pol II to the *I15* locus, including the transcribed region in IL-33-cultured memory Th2 cells, was detected. These results indicate that IL-33, as well as the combination of IL-2 and IL-25, remodels chromatin structure to be permissive for transcription at the *I15* locus in memory Th2 cells.




Figure 2. IL-33 Selectively Remodels Chromatin Structure at the *Il5* Locus in Memory Th2 Cells Independently of TCR Stimulation

(A) Schematic representation of the mouse *Il5* locus. The locations of primers and probes (upstream region 2 [U2] to *Il5* intron 1 [int.1]) and exons are indicated. (B) ChIP assays were performed with anti-trimethyl histone H3-K4, anti-acetyl histone H3K9, and anti-trimethyl histone H3K27 at the *Il5* locus from effector Th1, effector Th2, freshly prepared memory Th2, and memory Th2 cells cultured with IL-33 for 5 days. The relative intensities (relative to input DNA) of these modifications were determined by quantitative RT-PCR analysis. More than three independent experiments were performed and showed similar results. (C) The binding of p300 and pol II to the *Il5* locus in the indicated cell types was detected by ChIP with quantitative RT-PCR analysis.

Two independent experiments were performed and showed similar results. Three technical replicates were performed with quantitative RT-PCR (B and C). See also Figure S2.

Because TCR stimulation was not included in this culture system, it appears as though the observed chromatin remodeling was solely induced by cytokine signaling.

The IL-33-ST2 Pathway Enhances IL-5 Production by Memory Th2 Cells In Vivo

We used *Il1rl1*-deficient (*Il1rl1*^{-/-}) mice in order to directly demonstrate the involvement of the IL-33-ST2 pathway in the generation of IL-5-producing memory Th2 cells. In the absence of ST2, effector Th2 cell differentiation was not impaired, and memory Th2 cells were generated normally in vivo (Figures S3A and S3B). As expected, IL-33-induced IL-5 augmentation was not observed in *Il1rl1*^{-/-} memory Th2 cells (Figure 3A). Next, we assessed the effect of IL-33 on the IL-5 production of memory Th2 cells in vivo, as illustrated in Figure 3B. Administration of IL-33 increased ST2 expression (Figure 3C) and IL-5 production (Figure 3D) of *Il1rl1*^{+/+} memory Th2 cells but did not substantially alter expression of ST2 or IL-5 production by *Il1rl1*^{-/-} memory Th2 cells. These results indicate that memory Th2 cells respond to IL-33 in vivo by increasing ST2 expression and producing IL-5, as was observed in memory Th2 cells after cultivation with IL-33 in vitro.

We also generated non-transgenic memory CD4⁺ T cells by using an OVA-alum (OVA with aluminum) immunization system in vivo, as depicted in Figure 3E. A substantial proportion of non-TCR transgenic memory CD4⁺ T cells expressed ST2 (Figure 3F and Figure S3C), and IL-33-induced IL-5 augmentation was detected in *Il1rl1*^{+/+} memory CD4⁺ T cells, but not in *Il1rl1*^{-/-} memory CD4⁺ T cells (Figure 3G). Thus, the IL-33-ST2 pathway is critical for the induction of ST2 expression and generation of IL-5-producing memory Th2 cells in vivo.

Memory-Th2-Cell-Dependent Eosinophilic Airway Inflammation and AHR Are Ameliorated by the Depletion of IL-33 or ST2

In order to assess the role of the IL-33-ST2 pathway in the pathological function of memory Th2 cells, we used memory-Th2-cell-dependent airway-inflammation models, as illustrated in Figure 4A. The expression of *Il33* in the lung was increased after OVA challenge by inhalation, whereas the expression of *Il33* in the spleen was not increased even after OVA challenge (Figure 4B). In this model, ST2-expressing cells were increased after OVA challenge in the lung, and highly ST2-expressing cells were found in the CXCR3⁻ memory Th2 cell population (indicated by




Figure 3. The IL-33-ST2 Pathway Enhances IL-5 Production by Memory Th2 Cells In Vivo

(A) Intracellular-staining profiles of IL-5 and IL-4 in *Il1rl1*^{+/+} or *Il1rl1*^{-/-} memory Th2 cells before (left, control) and after (right, IL-33) cultivation with IL-33. Five independent experiments were performed and showed similar results.

(B) Experimental protocols for the injection of IL-33 into the mice that received *Il1rl1*^{+/+} or *Il1rl1*^{-/-} memory Th2 cells.


(C) ST2 and CXCR3 expression profiles of KJ1⁺ memory Th2 cells recovered from the lungs of mice that received *Il1rl1*^{+/+} (left) or *Il1rl1*^{-/-} (right) memory Th2 cells.

(D) KJ1⁺ memory Th2 cells shown in (C) were stimulated in vitro with immobilized anti-TCR β for 6 hr. Intracellular-staining profiles of IL-5 and IL-4 are shown.

(E) Experimental protocols for the generation of non-TCR transgenic memory CD4⁺ T cells in vivo. (F) Cell-surface-expression profiles of ST2 and CXCR3 on *Il1rl1*^{+/+} or *Il1rl1*^{-/-} CD44⁺ memory type CD4⁺ T cells are shown.

(G) *Il1rl1*^{+/+} or *Il1rl1*^{-/-} memory CD4⁺ T cells shown in (F) were stimulated with OVA-pulsed antigen-presenting cells for 24 hr before (upper) and after (lower) cultivation with IL-33. Intracellular-staining profiles of IL-5 and CD44 are shown with the percentage of cells in each area.

Two independent experiments were performed and showed similar results, and five technical replicates were included (C, D, F, and G). See also Figure S3.



(legend on next page)

an arrow, Figure 4C, middle). Only a small number of ST2-expressing cells were detected in endogenous lung CD4⁺ T cells even after OVA challenge (Figure 4C, right).

Next, OVA-specific *Il1rl1*^{+/+} or *Il1rl1*^{-/-} memory Th2 cells were transferred into wild-type BALB/c recipients, and their ability to induce airway inflammation was assessed. Compared to the *Il1rl1*^{+/+} group, the *Il1rl1*^{-/-} group showed a significant decrease ($p < 0.01$; Mann-Whitney U test) in the number of inflammatory eosinophils in the bronchoalveolar lavage (BAL) fluid (Figures 4D and S4A). No obvious changes in numbers of infiltrated cells were detected in OVA-challenged *Il1rl1*^{+/+} and *Il1rl1*^{-/-} mice that had not received memory Th2 cells. Histological analysis also revealed a similar reduction in mononuclear cell infiltration into the peribronchiolar regions of the lungs (Figure 4E). Periodic acid-Schiff (PAS) staining showed decreased production of mucus in the *Il1rl1*^{-/-} group (Figure 4F). Conversely, similar eosinophilic infiltration into the BAL fluid was observed from the mice that received *Il1rl1*^{+/+} and *Il1rl1*^{-/-} effector Th2 cells that were challenged with OVA on days 1 and 3 (Figures S4B and S4C). These results support the observation that effector Th2 cells possess little reactivity to IL-33 and that this pathway is less important for induction of eosinophilic inflammation by effector Th2 cells than for induction by memory Th2 cells. We also performed a set of in vivo kinetics experiments to better define the timing of acquisition of IL-33 responsiveness by memory Th2 cells. Eosinophilic airway inflammation, IL-5-producing Th2 cells in the lung, and IL-5 in the BAL fluid were assessed 6 or 35 days after the transfer of *Il1rl1*^{+/+} and *Il1rl1*^{-/-} effector Th2 cells (Figures S4D–S4K). Six days after cell transfer, no significant difference was detected in these three parameters between the *Il1rl1*^{-/-} and *Il1rl1*^{+/+} groups (Figures S4D–S4G). In contrast, significant decreases in eosinophilic infiltration ($p < 0.01$; Mann-Whitney U test), generation of IL-5-producing Th2 cells, and IL-5 production were observed in the day-35 *Il1rl1*^{-/-} group (Figures S4H–S4K). We also examined the OVA-induced airway inflammation in OVA-immunized *Il1rl1*^{+/+} and *Il1rl1*^{-/-} mice at different time points (12 or 45 days after OVA immunization) (Figures S4L–S4S). Significantly decreased infiltration of eosinophils into the BAL fluid ($p < 0.01$; Mann-Whitney U test), reduced IL-5-producing Th2 cells in the lung, and decreased IL-5 production in the BAL fluid were observed in the *Il1rl1*^{-/-} group 45 days after, but not 12 days after, the last immunization. These results indicate that ST2-mediated induction of IL-5 and exacerbation of eosinophilic airway inflammation were acquired by memory Th2 cells 35 days after effector Th2 cell transfer or 45 days after antigenic immunization, but not at the earlier time points analyzed.

The amount of IL-5 in the BAL fluid was significantly lower ($p < 0.01$; Mann-Whitney U test) in the *Il1rl1*^{-/-} memory Th2 cell group than in the *Il1rl1*^{+/+} group, whereas the amount of IL-4 was almost equivalent between the two groups (Figure 4G). We also detected a modest but significant reduction in IL-13 ($p < 0.05$; Mann-Whitney U test). Consistent with these observations, fewer IL-5-producing memory Th2 cells were detected in the lungs of mice from the *Il1rl1*^{-/-} group than in those from the *Il1rl1*^{+/+} group after OVA inhalation (Figure 4H, left), whereas decreases in IL-4- and IL-13-producing cells were less prominent. Th2-cell-associated cytokine production was not substantially different between endogenous *Il1rl1*^{+/+} and *Il1rl1*^{-/-} CD4⁺ T cells (Figure 4H, right). In addition, comparable proportions of Th2-cell-associated cytokine-producing memory Th2 cells were observed in the spleens of mice from the *Il1rl1*^{-/-} and *Il1rl1*^{+/+} groups (Figure S4T). These data are consistent with the absence of change in *I33* expression in the spleen after OVA challenge (Figure 4B). We also analyzed the degree of AHR in the allergy-induced mice, which received *Il1rl1*^{+/+} or *Il1rl1*^{-/-} memory Th2 cells, by measuring methacholine-induced airflow obstruction with a mechanical ventilator. The degree of AHR in mice that received *Il1rl1*^{-/-} memory Th2 cells was lower than that of mice that received *Il1rl1*^{+/+} memory Th2 cells ($p < 0.05$; Mann-Whitney U test) (Figure 4I).

Finally, we assessed the relative contribution of memory Th2 cells to eosinophilic inflammation given that it is already known that ILC2s can respond to IL-33 by producing IL-5 in the lung (Halim et al., 2012). We examined the effect of the depletion of ILC2s on memory-Th2-cell-induced airway inflammation in the lung by using CD90.2 antibody. In brief, CD90.1⁺ memory Th2 cells were transferred into CD90.2 *Rag2*^{-/-} mice, and CD90.2⁺ ILC2s were depleted by the administration of CD90.2 antibody (Figures S4U and S4V). These mice were challenged with inhaled OVA four times. The number of infiltrated eosinophils and the concentration of IL-5 in the BAL fluid were found to be similar between control and ILC2-depleted groups (Figures 4J and 4K). Therefore, at least in this system, the contribution of ILC2s to eosinophilic inflammation is relatively minor.

***I33*^{-/-} Mice Have Impaired Generation of IL-5-Producing Memory Th2 Cells and Reduced Eosinophilic Airway Inflammation**

We next assessed the function of IL-33 on memory Th2 cells by using *I33*^{+/+} and *I33*^{-/-} mice as recipients with or without OVA challenge (Figures S5A and S5B). First, we assessed the effect of endogenous IL-33 on memory Th2 cells in the steady state.

Figure 4. The Pathogenicity of Memory Th2 Cells Is Ameliorated by Loss of IL-33-ST2 Signaling

(A) Experimental protocols for memory-Th2-cell-dependent allergic inflammation.

(B–I) Mice were treated as described in (A). (B) Quantitative RT-PCR analysis of *I33* in the spleen or lungs. (C) ST2 and CXCR3 expression profiles of lung KJ1⁺ memory Th2 cells from mice with no challenge (left) or OVA challenge (center) and endogenous CD4⁺ T cells from mice with OVA challenge (right). (D) The absolute cell numbers of eosinophils (Eos), neutrophils (Neu), lymphocytes (Lym), and macrophages (Mac) in the BAL fluid are shown. Mean values (five mice per group) are shown with SDs. (E and F) Lungs were fixed and stained with H&E or PAS. A representative staining pattern is shown. Scale bars represent 100 μ m. (G) ELISA of the indicated cytokines in the BAL fluid from the experimental groups shown in (D). (H) Intracellular-staining profiles of the indicated cytokines in *Il1rl1*^{+/+} or *Il1rl1*^{-/-} memory Th2 cells in the lung. (I) Lung resistance (RL) was assessed in response to increasing doses of methacholine. The mean values (five mice per group) are shown with SDs.

(J) The absolute cell numbers of leukocytes in the BAL fluid. Mean values (five mice per group) are shown with SDs.

(K) ELISA analysis of the indicated cytokines in the BAL fluid from the experimental groups with memory Th2 cell transfer shown in (J).

Three (B–H) or two (J and K) independent experiments were performed and showed similar results (** $p < 0.01$; * $p < 0.05$). Three technical replicates were included in quantitative RT-PCR analysis (B). Five technical replicates were included in ELISA on the BAL fluid samples (G and K). See also Figure S4.




Figure 5. Reduced Memory-Th2-Cell-Dependent Airway Inflammation in *Il33^{-/-}* Mice

(A) ST2 and CXCR3 expression profiles of KJ1⁺ memory Th2 cells prepared from the spleens and lungs of *Il33^{+/+}* or *Il33^{-/-}* recipients.

(B) Quantitative RT-PCR analysis of *Il1r1* in lung memory Th2 cells from *Il33^{+/+}* or *Il33^{-/-}* recipients. Relative expression (normalized to *Hprt*) is shown with SDs.

(legend continued on next page)

Compared to memory Th2 cells generated in *Il33*^{+/+} mice, memory Th2 cells generated in *Il33*^{-/-} mice (without OVA inhalation) showed a moderate reduction of ST2 expression (Figures 5A and 5B) and significant reduction of IL-5-producing cells (Figure 5C) ($p < 0.05$; Mann-Whitney U test). We also examined memory-Th2-cell-dependent airway inflammation by using *Il33*^{+/+} and *Il33*^{-/-} mice as recipients (Figure S5B). The OVA-induced highly ST2-expressing CXCR3⁻ population was not detected when memory Th2 cells were transferred into *Il33*^{-/-} mice (Figure 5D). Compared to the *Il33*^{+/+} group, mice from the *Il33*^{-/-} group displayed significantly decreased eosinophilic infiltration ($p < 0.01$; Mann-Whitney U test; Figure 5E), and the amount of IL-5 in the BAL fluid was significantly decreased ($p < 0.01$; Mann-Whitney U test; Figure 5F). No obvious changes in the numbers of infiltrated cells were detected in OVA-challenged *Il33*^{+/+} and *Il33*^{-/-} mice that had not received memory Th2 cells (Figure 5E). Consistent with these observations, fewer IL-5-producing memory Th2 cells were detected in the lungs of mice from the *Il33*^{-/-} group than in those of mice from the *Il33*^{+/+} group after OVA inhalation, whereas the percentages of IL-4- or IL-13-producing cells were equivalent (Figure 5G, left). No substantial changes in Th2-cell-associated cytokine production were detected between *Il33*^{+/+} and *Il33*^{-/-} endogenous CD4⁺ T cells (Figure 5G, right). Thus, endogenous IL-33 from the recipient mice appears to be critical for the induction of memory-Th2-cell-dependent eosinophilic airway inflammation.

p38 Is a Major Downstream Target of IL-33-Dependent IL-5 Augmentation in Memory Th2 Cells

Next, we sought to identify which signaling pathway downstream of the ST2 receptor was responsible for the IL-33-dependent augmentation of IL-5 production by memory Th2 cells. Given that IL-33 has been reported to induce MAPK activation and NF- κ B phosphorylation in mast cells (Schmitz et al., 2005), we first examined the effect of chemical inhibitors of several components of these two pathways. We assessed the p38 MAPK inhibitor SB203580, the MEK inhibitor U0126, the JNK inhibitor SP600125, and the PI3K inhibitor Wortmannin. SB203580 inhibited the IL-33-induced IL-5 augmentation in memory Th2 cells, whereas the other inhibitors had little effect on IL-5 production (Figure 6A). No change in IL-4 production was detected after treatment with SB203580. We also used SB203580 to assess whether the IL-2- and IL-25-induced IL-5 augmentation in memory Th2 cells was dependent on p38 MAPK pathway. As expected, SB203580 inhibited IL-2- and IL-25-induced IL-5 augmentation in memory Th2 cells (Figure S6). Phosphorylation of p38 was induced by IL-33 and was inhibited by SB203580 (Figure 6B). A very small increase in p38 phosphorylation was detected after culture with IL-2. Significant reductions in

mRNA expression of *Il5* and *Il1r1* were detected in response to SB203580 treatment of memory Th2 cells stimulated with IL-33; however, no significant reduction was observed in *Il4*, *Il13*, or *Gata3* ($p < 0.01$; Mann-Whitney U test; Figure 6C). We also detected marked reduction of ST2 after SB203580 treatment of IL-33-stimulated memory Th2 cells (Figure 6D). We next analyzed the effect of SB203580 on histone modifications at the *Il5* locus in memory Th2 cells. Memory Th2 cells cultured with IL-33 in the presence of SB203580 showed reduced modifications of H3-K4 methylation and H3-K9 acetylation at the *Il5* locus, but not at the conserved GATA3 response element or Va enhancer regions, which are located near the *Il13* promoter and downstream of the *Il4* locus, respectively (Figure 6E). Specific reduction of *Il5* and *Il1r1* expression in response to siRNA-mediated silenced p38 in memory Th2 cells was also detected, whereas silencing of p38 did not change IL-4 or IL-13 expression (Figure 6F). These results indicate that IL-33 selectively activates p38, increases the expression of ST2, and augments the production of IL-5 in memory Th2 cells.

Human IL-33 Enhances IL-5 Production in Memory CD4⁺ T Cells from the Polyps of Patients with ECRS

Finally, we sought to gain more insight into the possible pathophysiological effect of IL-33 on memory Th2 cells in human disease. We analyzed CD45RO⁺ memory CD4⁺ T cells from the nasal polyps of patients with ECRS, which is characterized by IL-5-dependent accumulation of large numbers of eosinophils (Gevaert et al., 2006). We included samples from ECRS and NECRS patients and categorized them by the number of eosinophils found in the nasal polyps (Zhang et al., 2008). All patients signed informed-consent forms, and the study was approved by the ethics committee of the Chiba University Graduate School of Medicine and each participating hospital (1006). The number of IL-33⁺ endothelial cells in the nasal polyps was comparable between ECRS and NECRS patients (data not shown). However, compared to nasal polyps from NECRS patients, those from ECRS patients showed significantly elevated numbers of IL-33⁺PECAM1⁺ endothelial cells ($p < 0.05$; Mann-Whitney U test; Figure 7A). In addition, the baseline expression of *IL4* and *IL5* (encoding Th2 cell cytokines), *IL1RL1*, and *GATA3* was higher in the ECRS polyps (Figure 7B). In contrast, the expression of *TBX21* was lower in the ECRS polyps. These results prompted us to assess the effect of IL-33 on Th2 cell cytokine production of memory CD4⁺ T cells from nasal polyps of these patients. As a control, we analyzed the effect of IL-33 on cytokine expression by the CD45RO⁺CD4⁺ T cell population of peripheral-blood mononuclear cells (PBMCs) from healthy donors. Very little expression of ST2 was detected on CD45RO⁺CD4⁺ T cells from PBMCs, and no obvious augmentation in

(C) Intracellular-staining profiles of IL-5 and KJ1.26 in lung memory Th2 cells and endogenous CD4⁺ T cells from *Il33*^{+/+} or *Il33*^{-/-} recipients.

(D) ST2 and CXCR3 expression profiles of lung KJ1⁺ memory Th2 cells in *Il33*^{+/+} or *Il33*^{-/-} recipients after OVA challenge.

(E) The absolute numbers of leukocytes in BAL fluid from *Il33*^{+/+} or *Il33*^{-/-} mice transferred with or without memory Th2 cells are shown. Samples were collected 2 days after the last OVA challenge. The mean values (five mice per group) are shown with SDs.

(F) ELISA of the indicated cytokines in the BAL fluid from each experimental group shown in (E).

(G) Intracellular-staining profiles of the indicated cytokines in lung memory Th2 cells and endogenous CD4⁺ T cells from *Il33*^{+/+} or *Il33*^{-/-} mice after OVA challenging four times.

Two (A–C) or three (D–G) independent experiments were performed and showed similar results (** $p < 0.01$; * $p < 0.05$). Three technical replicates were performed with quantitative RT-PCR (B). Five technical replicates were performed with ELISA in BAL fluid (F). See also Figure S5.




Figure 6. p38 Signaling Is Crucial for IL-33-Dependent IL-5 Induction by Memory Th2 Cells

(A) Intracellular-staining profiles of IL-5 and IL-4 in IL-33-treated memory Th2 cells with the indicated chemical inhibitors.

(B) The phosphorylated p38 (p-p38) and total p38 (p38) in freshly prepared memory Th2 cells stimulated with IL-2 or graded amounts of IL-33 with or without SB203580.

(C) Quantitative RT-PCR analysis of the indicated genes in memory Th2 cells cultured with IL-33 with or without SB203580. Four independent experiments were performed and showed similar results (**p < 0.01).

(D) Expression profiles of ST2 on memory Th2 cells treated with IL-33 with or without SB203580.

(legend continued on next page)

IL-5 expression or production was detected after IL-33 treatment (Figures S7A–S7C). However, IL-33 dramatically enhanced *IL5* expression in CD45RO⁺CD4⁺ T cells from nasal polyps of ECRS patients ($p < 0.01$; Mann-Whitney U test; Figure 7B). Modest enhancement of *IL13* expression was also detected ($p < 0.05$; Mann-Whitney U test). In addition, the expression of *IL1RL1* was enhanced dramatically after IL-33 treatment, which supported the results obtained from analysis of murine memory Th2 cells (Figure 1). In contrast, no obvious effect of IL-33 on the expression of *IL5* or *IL13* was detected in CD45RO⁺CD4⁺ T cells from nasal polyps of NECRS patients. Furthermore, the expression and production of IL-5 and the *IL1RL1* expression that was enhanced by IL-33 in CD45RO⁺CD4⁺ T cells from nasal polyps of ECRS patients were selectively inhibited by SB203580 treatment ($p < 0.01$; Mann-Whitney U test; Figures 7C and 7D). These results indicate that IL-33 specifically induces enhanced expression of *IL1RL1* and IL-5 in CD45RO⁺CD4⁺ T cells from nasal polyps of ECRS patients and that p38 activation is required for IL-33-induced IL-5 augmentation. Thus, IL-33-ST2-p38 signaling might play an important role in the induction of pathogenicity in tissue-infiltrating memory CD4⁺ T cells in human chronic allergic inflammatory diseases such as ECRS.

DISCUSSION

Herein, we have identified memory Th2 cells as a critical target of IL-33 in the pathogenesis of allergic airway inflammation in both the murine and the human immune systems. IL-33 induced increased expression of ST2 on memory Th2 cells and also enhanced production of IL-5 both in vitro and in vivo. IL-33 exposure induced chromatin remodeling at the *Il5* locus. We found that p38 MAPK was a downstream target of IL-33-ST2 signaling in memory Th2 cells. In vivo, the depletion of IL-33 or ST2 attenuated memory-Th2-cell-mediated allergic responses in the airway. Memory CD4⁺ T cells in the nasal polyps of ECRS patients showed increased IL-5 expression after stimulation with IL-33, and IL-33 was highly expressed in the chronic inflammatory polyps of ECRS patients. Thus, the IL-33-ST2-p38 pathway could be a potential therapeutic target for treatment of chronic allergic inflammation induced by memory Th2 cells.

IL-33-mediated production of IL-5 and IL-13 in ILC2s depends on the phosphorylation of p38 (Furusawa et al., 2013), and IL-33 increases phosphorylation of p38 in mast cells (Liew et al., 2010). In human T cells, IL-5 production induced by TCR stimulation is dependent on p38 activity (Maneechotesuwan et al., 2007; Mori et al., 1999). Likewise, we found that the p38-mediated signaling pathway is critical for IL-33-induction of IL-5 expression in both murine and human memory T cells. Thus, the p38 MAPK pathway appears to be critical for the production of IL-5 in various types of cells, including memory Th2 cells.

Chromatin remodeling of *Il4* is dependent on the calcineurin-NFAT pathway (Ansel et al., 2006), whereas that of IL-5 and IL-13 appears to be more dependent on NF- κ B, AP-1, or other

transcription factors rather than NFAT (Guo et al., 2009; Wang et al., 2006). In the current study, we found that the p38 MAPK pathway was activated by IL-33 and was responsible for the induction of chromatin remodeling of the *Il5* locus and thus left the chromatin signature at the *Il4* and *Il13* loci almost unchanged. Therefore, this might represent a connection between the IL-33-p38 MAPK pathway and selective chromatin remodeling of the *Il5* locus.

An important finding from the present study is that IL-33-induced chromatin remodeling at the *Il5* locus in memory Th2 cells occurs independently from TCR stimulation. TCR stimulation is indispensable for the induction of chromatin remodeling at the Th1 and Th2 cell cytokine-encoding loci during differentiation of naive CD4⁺ T cells into effector Th1 and Th2 cells (Nakayama and Yamashita, 2010). However, we have shown that the cytokine IL-33 alone is capable of selectively inducing chromatin remodeling at the *Il5* locus in memory Th2 cells. These results might indicate that IL-33 possesses a unique ability to induce chromatin remodeling at the *Il5* locus if the IL-33 receptor ST2 is expressed. Indeed, IL-2, IL-7, or IL-25 did not induce chromatin remodeling at the *Il5* locus in memory Th2 cells, although their receptors were expressed on memory Th2 cells. The combination of IL-2 and IL-25 also induced chromatin remodeling at the *Il5* locus in memory Th2 cells, as shown previously in ILC2s (Halim et al., 2012), suggesting that similar mechanisms might operate cytokine-dependent IL-5 induction in memory Th2 cells and ILC2s. In ILC2s, IL-33 is reported to be more potent than IL-25 in inducing IL-13 production and AHR (Barlow et al., 2013). At the *Il5* locus, we detected permissive histone marks accompanied by binding of p300 and pol II in memory Th2 cells stimulated with IL-33. Therefore, the activation of the IL-33-ST2-p38 axis might induce the formation of a chromatin-remodeling complex, including the HAT complex, and recruit it to the *Il5* locus in memory Th2 cells.

We have demonstrated that memory Th2 cells are an important target of IL-33 in the pathogenesis of airway inflammation. We detected increased expression of *Il33* mRNA in the lung after OVA challenge, which is consistent with the notion that tissue damage leads to the release of IL-33 from structural cells, such as epithelial cells and endothelial cells in the lung (Préfontaine et al., 2009; Préfontaine et al., 2010), and that IL-33 is expressed higher in asthmatic patients (Préfontaine et al., 2009). IL-33 secreted around the inflammatory airways might increase ST2 expression and IL-5 production by memory Th2 cells that are either resident in or migrating through the lung tissue. Therefore, IL-33 might enhance allergic airway responses through the induction of our proposed IL-5-producing pathogenic memory Th2 cells in the airway (Endo et al., 2014; Endo et al., 2011; Hegazy et al., 2010; Islam et al., 2011; Upadhyaya et al., 2011; Wang et al., 2010). Although it is already known that ILC2s respond to IL-33 to produce IL-5 in the lung, the depletion of ILC2s in *Rag2*^{-/-} mice by anti-CD90.2 antibody treatment did not affect memory-Th2-cell-dependent airway inflammation.

(E) ChIP assays were performed as shown in Figure 2B. Histone modifications at the *Il5* locus in memory Th2 cells treated with IL-33 with or without SB203580 were measured by quantitative RT-PCR analysis.

(F) Effect of silenced p38 on *Il5* expression in IL-33-cultured memory Th2 cells. Memory Th2 cells were introduced to control p38 siRNA and cultured with IL-33 for 5 days, and quantitative RT-PCR analysis of the indicated molecules after 4 hr stimulation with immobilized anti-TCR β is shown.

At least three (A–D) or two (E and F) independent experiments were performed and showed similar results. See also Figure S6.




Figure 7. Human IL-33 Enhances IL-5 Production in Memory CD4⁺ T Cells Prepared from Nasal Polyps of ECRS Patients

(A) Immunofluorescent analysis (with staining for IL-33 [red], PECAM [green], and TOPRO3 [blue]) shows a representative section of nasal polyps from NECRS (left) or ECRS (right) patients. The frequency of IL-33⁺PECAM1⁺ cells among PECAM⁺ cells of the nasal polyps from patients is shown (mean ± SD; n = 6 for ECRS and n = 8 for NECRS).

(B) Quantitative RT-PCR analysis of relative expression of the indicated genes in human memory CD4⁺ T cells from nasal polyps (n = 11 for ECRS, n = 6 for NECRS) was performed after 4 hr stimulation with PMA plus ionomycin. Relative expression (normalized to 18S) with SD is shown. Mean values and SDs are shown.

(C) Human nasal memory CD4⁺ T cells were cultured with IL-33 with or without SB203580 for 5 days. Quantitative RT-PCR analysis of the indicated cytokines in these cells after 4 hr stimulation with PMA plus ionomycin is shown.

(D) ELISA (n = 8 for ECRS and n = 5 for NECRS) of the indicated cytokines secreted by IL-33-cultured memory CD4⁺ T cells stimulated with PMA plus ionomycin for 16 hr. The mean values of triplicate cultures with SDs are shown.

More than five independent experiments in each group were performed and showed similar results (**p < 0.01; *p < 0.05; C and D). Three technical replicates were performed with quantitative RT-PCR and ELISA (B–D). See also Figure S7.

Thus, according to the experimental systems we used, IL-33 appears to act mainly on memory Th2 cells to increase their ability to produce IL-5 and exacerbate eosinophilic inflammation. It remains unknown whether IL-33 induces recruitment of memory Th2 cells to the inflamed lung, given that IL-33 can also act as a chemoattractant for Th2 cells (Komai-Koma et al., 2007).

ECRS is a chronic inflammatory disease characterized by prominent accumulation of eosinophils in the sinuses and nasal polyp tissue (Gevaert et al., 2006). Functionally distinct populations of memory CD4⁺ T cells might be present within the nasal polyps of ECRS and NECRS (Th1 cell type for NECRS and Th2 cell type for ECRS). We detected more IL-33-producing cells in